Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender an offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
The latest move follows a definitive agreement signed by the company for the acquisition last month.
Related: Merck To Buy Acceleron For US$11.5B
Merck, through its subsidiary, commenced a cash tender offer to acquire Acceleron’s all outstanding shares, for US$180 per share, as announced on October 12 of this year.
Merck stated, “As previously announced on 29 October 2021, the tender offer will expire at 5:00 p.m., Eastern Time, on 18 November 2021, unless further extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canada Investigates Major Grocers for Anticompetitive Practices
May 26, 2024 by
CPI
John Hess Scrambles to Secure Shareholder Approval for $53 Billion Chevron Merger
May 26, 2024 by
CPI
Petrobras Retains Refineries and Gas Pipeline in CADE’s Landmark Reversal
May 26, 2024 by
CPI
Meta Proposes New Data Limits on Facebook Marketplace in UK Amid CMA Oversight
May 26, 2024 by
CPI
EU Industry Chief Calls for Unified Tech Regulations Between US and Europe
May 26, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI